ZIM
HRTX icon

Zacks Investment Management’s Heron Therapeutics HRTX Stock Holding History

Zacks Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,899
Closed -$30.8K – 798
2025
Q2 		$30.8K Buy
+14,899
New +$30.4K ﹤0.01% 689
2024
Q4 		– Sell
-475,575
Closed -$946K – 721
2024
Q3 		$946K Buy
475,575
+11,320
+2% +$27K 0.01% 408
2024
Q2 		$1.62M Buy
464,255
+27,782
+6% +$85.4K 0.02% 316
2024
Q1 		$1.21M Buy
436,473
+125,044
+40% +$314K 0.01% 381
2023
Q4 		$529K Buy
+311,429
New +$343K 0.01% 459

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zacks Investment Management's HRTX Position: Q3 2025 in Review

Zacks Investment Management sold out of Heron Therapeutics (HRTX) in Q3 2025, closing a stake of 14,899 shares — an estimated $30.8K sold.

Zacks Investment Management first reported a position in HRTX in Q4 2023 and held it in 5 quarters. The position peaked at $1.62M in Q2 2024. 172 funds tracked by Wall St. Rank hold HRTX as of Q3 2025.

  • Zacks Investment Management reported no remaining Heron Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Zacks Investment Management sold 14,899 Heron Therapeutics shares in Q3 2025, an estimated $30.8K.
  • Zacks Investment Management first reported a position in Heron Therapeutics in Q4 2023 and held it in 5 quarters.
  • Zacks Investment Management's Heron Therapeutics position peaked at $1.62M in Q2 2024.
  • 172 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2025.

Based on Zacks Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.